SEC Form 4 · accession 0001140361-18-029621
Arbutus Biopharma Corp · ABUS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Keith S Manchester
Director
Period of report
Jun 19, 2018
Accepted (ET)
Jun 22, 2018 · 5:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001447028
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (Right to Buy)F2,F1 | $6.75 | Jun 19, 2018 | A | 22,000 | A | Jun 19, 2018 | Jun 19, 2028 | Common Shares | 22,000 | 22,000 | D |
Explanation of responses
- F1The shares underlying this option fully vested on June 19, 2018.
- F2Dr. Manchester is the Head of Life Sciences and a Portfolio Manager at QVT Financial LP and serves as a director on behalf of QVT Financial LP and its affiliates. Dr. Manchester holds these stock options for the benefit of certain funds managed by QVT Financial LP.